Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ImmunityBio (IBRX) EPS (Basic) (2016 - 2026)

ImmunityBio has reported EPS (Basic) over the past 12 years, most recently at -$0.06 for Q4 2025.

  • Quarterly EPS (Basic) rose 14.29% to -$0.06 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.38 through Dec 2025, up 35.59% year-over-year, with the annual reading at -$0.38 for FY2025, 35.59% up from the prior year.
  • EPS (Basic) was -$0.06 for Q4 2025 at ImmunityBio, up from -$0.07 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.06 in Q4 2025 and troughed at -$0.38 in Q4 2023.
  • The 5-year median for EPS (Basic) is -$0.22 (2021), against an average of -$0.2.
  • Year-over-year, EPS (Basic) crashed 110.0% in 2021 and then skyrocketed 81.58% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.23 in 2021, then decreased by 17.39% to -$0.27 in 2022, then plummeted by 40.74% to -$0.38 in 2023, then skyrocketed by 81.58% to -$0.07 in 2024, then increased by 14.29% to -$0.06 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EPS (Basic) are -$0.06 (Q4 2025), -$0.07 (Q3 2025), and -$0.1 (Q2 2025).